Open access · CC-BY
via OpenAlex
EVALUATION OF THE EFFECT OF METFORMIN ON SERUM INFLAMMATORY BIOMARKERS (CRP, IL-6) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Muhammad Mushtaq, Saman Tariq, Umer Mushtaq, Dr Muhammad Usman, Dr Fajar Khalid, Saira Khalil, Saqlain Ghazanfar
The Research of Medical Science Review · 2025
Abstract
Background: Type 2 Diabetes Mellitus (T2DM) is characterized by insulin resistance and low-grade systemic inflammation, which contributes to the progression of the disease and its complications. Metformin, a common first-line treatment for T2DM, is primarily known for its glucose-lowering effects, but emerging evidence suggests it may also modulate inflammatory biomarkers such as C-reactive protein (CRP) and interleukin-6 (IL-6). Objective: This study aimed to evaluate the effect of Metformin on serum levels of CRP and IL-6 in patients with T2DM and compare the outcomes with a control group. Study Design and Setting: A randomized controlled trial was conducted in Shalamar Medical & Dental College, Lahore from November 2024 to April 2025. Methodology: Seventy patients with T2DM were allocated to the Metformin group, and seventy patients were assigned to the control group. Baseline and post-treatment serum CRP and IL-6 levels were measured using enzyme-linked immunosorbent assays (ELISA). The Metformin group received 500 mg of Metformin twice daily, while the control group did not receive any specific treatment. Paired t-tests were used for within-group comparisons, and independent t-tests assessed differences between groups. Results: The Metformin group showed a reduction in both CRP (−2.35 ± 3.41) and IL-6 (−0.36 ± 3.28), while the control group showed a smaller reduction in CRP (−2.07 ± 3.92) and IL-6 (−0.77 ± 3.21). However, no significant differences were observed between the two groups (p > 0.05). Conclusion: The study found no significant effect of Metformin on serum CRP and IL-6 levels in T2DM patients over the 12-week period. Long-term studies with larger sample sizes are needed to explore Metformin's potential anti-inflammatory effects.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- Canonical
- link ↗
- Fetched
- 2026-10-15 MST
Cite this
APA
Mushtaq, M., Tariq, S., Mushtaq, U., Usman, D.M., Khalid, D.F., Khalil, S., & Ghazanfar, S. (2025). EVALUATION OF THE EFFECT OF METFORMIN ON SERUM INFLAMMATORY BIOMARKERS (CRP, IL-6) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. <em>The Research of Medical Science Review</em>. https://openalex.org/W7220633661
Vancouver
Mushtaq M, Tariq S, Mushtaq U, Usman DM, Khalid DF, Khalil S, et al. EVALUATION OF THE EFFECT OF METFORMIN ON SERUM INFLAMMATORY BIOMARKERS (CRP, IL-6) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. The Research of Medical Science Review. 2025.
BibTeX
@article{muhammad2025EVALUA,
title = {EVALUATION OF THE EFFECT OF METFORMIN ON SERUM INFLAMMATORY BIOMARKERS (CRP, IL-6) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS},
author = {Muhammad Mushtaq and Saman Tariq and Umer Mushtaq and Dr Muhammad Usman and Dr Fajar Khalid and Saira Khalil and Saqlain Ghazanfar},
journal = {The Research of Medical Science Review},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Fatima Jinnah Medical University 2022
Open access · CC-BY
Correlation of inflammatory biomarkers with disease severity in hospitalised patients of COVID-19 at presentation
PubMed Central 2014
Preprint · CC-BY
Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes
Nutrients 2024
Open access · CC-BY
Effect of Time-Restricted Eating on Circulating Levels of IGF1 and Its Binding Proteins in Obesity: An Exploratory Analysis of a Randomized Controlled Trial
Frontiers in Endocrinology 2026
Open access · CC-BY
Case Report: Efficacy and safety of SGLT2 inhibitors in patients with Alström syndrome: a follow-up report of two siblings from the same family
Frontiers in endocrinology 2026
Open access · OA
Case Report: Efficacy and safety of SGLT2 inhibitors in patients with Alström syndrome: a follow-up report of two siblings from the same family.
Nutrition & Metabolism 2021
Open access · CC-BY